Acadia Pharmaceuticals Launches DAYBUE STIX for Rett Syndrome

New oral solution treatment now broadly available in the United States for the rare neurological disorder.

Apr. 7, 2026 at 5:55pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph showing the translucent, glowing internal structure of a small glass vial containing a luminescent liquid medication, conceptually representing a new treatment for the rare neurological disorder Rett syndrome.A new oral medication offers hope for managing the symptoms of Rett syndrome, a rare and devastating neurological disorder.San Diego Today

Acadia Pharmaceuticals has announced the launch of DAYBUE STIX (trofinetide), a dye- and preservative-free powder for oral solution, as a new treatment option for Rett syndrome, a rare and severe neurological disorder that primarily affects young girls.

Why it matters

Rett syndrome is a debilitating condition with no cure, so the availability of a new treatment option provides hope for patients and families affected by this disorder. DAYBUE STIX represents an important advancement in managing the symptoms and improving the quality of life for those living with Rett syndrome.

The details

DAYBUE STIX is an oral solution that was developed by Acadia Pharmaceuticals specifically for the treatment of Rett syndrome. The medication is now broadly available across the United States after receiving regulatory approval.

  • DAYBUE STIX was announced and launched on April 7, 2026.

The players

Acadia Pharmaceuticals Inc.

A biopharmaceutical company focused on developing and commercializing innovative medicines to address central nervous system disorders.

DAYBUE STIX

A dye- and preservative-free powder for oral solution developed by Acadia Pharmaceuticals as a treatment for Rett syndrome.

Got photos? Submit your photos here. ›

The takeaway

The launch of DAYBUE STIX represents an important new treatment option for the Rett syndrome community, providing hope and the potential to improve the quality of life for those living with this rare and debilitating neurological disorder.